Wolfgang Miesbach: Teclistamab Targets the Source of Pathogenic Autoantibodies
Wolfgang Miesbach, Head of the Hemostasis and Hemophilia Center at Department of Medicine II, University Hospital Frankfurt, shared a post on LinkedIn about a recent article by Johannes Thaler et al., published in JTH, adding:
”Seven patients, seven complete remissions, and one case that should not have worked.
Two papers have just been published on teclistamab in autoantibody-mediated coagulation disorders.
The drug is a bispecific antibody approved in multiple myeloma: it links the patient’s own T cells to B-cell maturation antigen (BCMA) on plasma cells and mature B cells and destroys them, removing the source of the autoantibody instead of the autoantibody itself.
Thaler, Cihan Ay et al. (Vienna) treated seven patients off-label: acquired von Willebrand disease (2), acquired factor XI deficiency (2), catastrophic APS (3). All reached complete remission, first laboratory response after a median of 14 days, median follow-up 52 weeks.
Dobbelstein, Andreas Tiede et al. (Hannover) report acquired haemophilia A that had already defeated CyDRi, daratumumab and two infusions of anti-CD19 CAR-T cells. FVIII 104 IU/dl by day 14, inhibitor cleared, remission now beyond one year.
Some important aspects:
- Bleeding and thrombotic phenotypes responded alike, which points to the plasma cell as the common denominator.
- The bispecific worked where CAR-T had failed. BCMA reaches cells that CD20 and CD19 do not.
- No cell manufacturing and no apheresis slot: any centre with myeloma experience could deliver this.
Adverse events: hypogammaglobulinaemia in every patient, with open-ended immunoglobulin replacement, and mild cytokine release syndrome (grade 1, fever alone, controlled with antipyretics) in 3 of 7.
The question is no longer whether it works, but when to use it.”
Title: Teclistamab for the treatment of autoantibody-mediated coagulation disorders
Authors: Johannes Thaler, Karoline Gleixner, Lisbeth Eischer, Gabriel Kammerer, Joachim Rettl, Lisa Sailer, Christian Sillaber, Peter Quehenberger, Maria Theresa Krauth, Paul Knöbl, Cihan Ay, Hermine Agis

Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines